Sanjivani Paranteral is a pharmaceutical manufacturer that has spent three decades learning to make sterile injectables without a single product failure - a track record that is its calling card in the export markets where it earns most of its money. It began in 1996 with one injectable plant in Navi Mumbai, added a second plant for tablets and capsules in Dehradun in 2009, and has since expanded into IV fluids and European nutraceuticals, transforming from a single-engine business into a multi-vertical platform. The recurring approach is to take a manufacturing capability built on sterile production - a high-barrier skill - and deploy it into adjacent markets where demand outstrips supply, whether that is injectables for emerging economies or IV fluids for a domestic market with a massive capacity gap.
Business segments
Three engines at different stages - a two-decade-old injectables and oral solids export business, a newly commissioned IV fluids plant addressing a structural domestic shortage, and a European nutraceutical manufacturing venture built for premium pricing - each anchored in sterile or quality-controlled manufacturing.
1. Sterile injectables and oral solids: the export backbone
A WHO GMP-certified manufacturer that sells essential and life-saving generic medicines to over 25 emerging-market countries, with injectables contributing more than half of product revenue.
- Two plants, one clean record - the company runs an injectable facility in Rabale, Navi Mumbai (founded 1996) and an oral solids plant in Dehradun (added 2009), both WHO GMP-certified, and claims not a single product failure in the last twenty years, which opens doors in regulated emerging markets.
- Injectables are the high-margin anchor - sterile injectables (ampoules, vials, liquid injectables) made up 53.5% of standalone product revenue in FY26, with tablets and capsules at 43.1% and nutraceuticals at 3.5%, because injectable manufacturing carries high barriers to entry and the company’s long history makes it a preferred supplier.
- Exports to markets competitors overlook - roughly four-fifths of standalone revenue comes from exports, with Latin America, the Middle East, Africa, and CIS countries together accounting for 76% of Q4 FY26 sales; the company holds about 30 product registrations in Latin and Central America alone, where pricing and margins are better than in crowded Southeast Asian markets.
- A portfolio built dossier by dossier - the company had approximately 160 products as of FY25, up from 100 in 2022, and filed 48 product dossiers in French-speaking African countries during the year, so growth comes from adding regulatory approvals that unlock new geographies and larger orders from existing customers.
- CDMO fills the plants - alongside its own brands, the company manufactures for other pharmaceutical firms like Gland, Macleods, and Vitabiotics under contract, which contributed about 11% of total revenue as of early 2024 and keeps the Dehradun oral solids plant - running at 40-45% capacity - steadily loaded.
2. SPL Infusion: IV fluids for a supply-starved domestic market
A newly built sterile facility in Pune that makes large-volume IV fluids in bottles, entering a market where annual demand is roughly three times the installed manufacturing capacity.
- Built where the gap is - the plant sits in Maharashtra, the only IV manufacturing facility in the entire western coastal stretch down to Kerala, which matters because transportation cost is a major reason for the supply shortage in North, East, and Northeast India.
- Demand already exceeds supply - Indian annual demand for IV fluids was cited at 720-768 crore bottles against an installed capacity of only 240-510 crore bottles, and the company had orders covering its full 5-million-bottle-per-month capacity before commercial production even began in September 2025.
- Scale-up is product-by-product - the facility is approved and commercialized, but individual product approvals are still being added, so output ramped from roughly INR 1.2 crore in Q3 FY26 to INR 2.7 crore in Q4 FY26, with capacity utilization at 20-23% as of February 2026 and a path to 40-50% expected by FY27.
- A public-private front-runner - the company is in talks with multiple government organizations for PPP-model IV plants and expects to finalise one or two such ventures, leveraging the same sterile manufacturing expertise that underpins its injectables business.
3. Alevia Healthcare: European-made nutraceuticals
A Prague-based joint venture that manufactures nutraceutical products with a ‘Made in Europe’ label, targeting premium pricing in developed and GCC markets while using Indian manufacturing for early-stage production.
- European label, Indian cost structure - the venture operates a late-stage manufacturing unit in Prague that was commissioned in FY25, with initial manufacturing stages outsourced to India, so it combines the cost advantage of Indian production with the pricing power of a European origin label in a global nutraceutical market worth over EUR 70 billion.
- An escape from the Indian price war - the domestic nutraceutical market suffers from low regulation, many players, pricing pressure, and no entry barriers, whereas the European venture gives the company access to developed markets where the ‘Made in Europe’ tag commands a premium.
Group structure and partners
A listed parent with a single subsidiary and one overseas joint venture, controlled by a promoter group that has led the company through a financial restructuring and back to positive net worth.
- Listed parent with a concentrated promoter holding - Sanjivani Paranteral Limited (BSE: 531569) is led by Chairman and Managing Director Ashwani Khemka, who held 27.13% as of FY25, with the promoter group collectively holding 31% as of March 2026.
- One subsidiary for IV fluids - SPL Infusion Private Limited, incorporated in February 2024, is 60.87% owned by Sanjivani and operates the Pune IV fluids facility built in partnership with Hindustan Antibiotics Limited.
- One joint venture for nutraceuticals - Alevia Healthcare S.R.O., based in Prague, Czech Republic, was entered into in May 2023 and handles European nutraceutical manufacturing and marketing.
- A balance sheet rebuilt from distress - legacy bank debts that had been classified as non-performing assets were settled in full via a one-time payment of INR 8.72 crores to an Asset Reconstruction Company in January 2022, after which charges on assets were released and the company’s net worth turned positive to INR 279 million by FY24.